Author pages are created from data sourced from our academic publisher partnerships and public sources.
Isolation of rare circulating tumour cells in cancer patients by microchip technology
Viable tumour-derived epithelial cells (circulating tumour cells or CTCs) have been identified in peripheral blood from cancer patients and are probably the origin of intractable metastatic disease.… Expand
Abiraterone in metastatic prostate cancer without previous chemotherapy.
BACKGROUND Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this… Expand
NCCN clinical practice guidelines in oncology: prostate cancer.
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
BACKGROUND Bone metastases are a major cause of morbidity and mortality in men with prostate cancer. Preclinical studies suggest that osteoclast inhibition might prevent bone metastases. We assessed… Expand
Changes in body composition during androgen deprivation therapy for prostate cancer.
- M. Smith, J. Finkelstein, +4 authors P. Kantoff
- The Journal of clinical endocrinology and…
- 1 February 2002
The aim of this study was to determine the effects of initial treatment with a GnRH agonist on body composition in asymptomatic men with nonmetastatic prostate cancer. Forty men with locally… Expand
Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer
Background Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide in men with nonmetastatic… Expand
Insulin sensitivity during combined androgen blockade for prostate cancer.
CONTEXT GnRH agonists markedly increase fat mass in men with prostate cancer, but little is known about the effects of treatment on insulin sensitivity. OBJECTIVE The objective of the study was to… Expand
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
- M. Smith, F. McGovern, +5 authors J. Finkelstein
- The New England journal of medicine
- 27 September 2001
BACKGROUND Treatment with a gonadotropin-releasing hormone agonist decreases bone mineral density and increases the risk of fracture in men with prostate cancer. We conducted a controlled study of… Expand
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
- M. Smith, J. Eastham, D. Gleason, D. Shasha, S. Tchekmedyian, N. Zinner
- The Journal of urology
- 1 June 2003
PURPOSE A multicenter double-blind, randomized, placebo controlled clinical trial was performed to assess the effect of zoledronic acid, a potent new bisphosphonate, on bone mineral density during… Expand
Adverse effects of androgen deprivation therapy and strategies to mitigate them.
CONTEXT Androgen-deprivation therapy (ADT) is a key component of treatment for aggressive and advanced prostate cancer, but it has also been associated with adverse effects on bone, metabolic,… Expand